AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Healthcare Licensing with Focus on Antibody Drug Conjugates, 2019 - 30+ Licensing News of Companies Across North America (57%), Europe (27%), and Asia (17%) - ResearchAndMarkets.com

May 9, 2019

DUBLIN--(BUSINESS WIRE)--May 9, 2019--The “Analytical Report for Healthcare Licensing with focus on Antibody Drug Conjugates” report has been added to ResearchAndMarkets.com’s offering.

Antibody-drug conjugates are an emerging novel class of anticancer treatment agents that combines the selectivity of targeted treatment with the cytotoxic potency of chemotherapy drugs. 30+ licensing news with focus on Antibody Drug Conjugates are reported and analyzed to provide a snapshot view of the current business trends here.

Analytical data coverage:

  • January 1, 2018 to March 31, 2019 licensing deals and negotiations
  • 30+ worldwide Antibody Drug Conjugates focused healthcare licensing news of companies across North America (57%), Europe (27%), Asia (17%)
  • Small-mid-large cap companies covered - LargeCap (40%)
  • Listed and non-listed companies included
  • 4 healthcare sub-sectors covered - Pharmaceuticals (34%), Biotech (55%), Healthcare Services (8%)
  • 14 medicine groups studied - Oncology (85%)
  • 8+ variables analyzed

User benefits:

  • Immediate access to current global licensing trends for Antibody Drug Conjugates
  • Succinct summaries of licensing deals and negotiations held worldwide
  • Quick to-the-point analytical references
  • In-depth updates on wider perspective of Antibody Drug Conjugates
  • Directions to the emerging business prospects

Key analysis in the report:

  • Leading countries in Antibody Drug Conjugates focused licensing
  • Most active healthcare sub-sectors in Antibody Drug Conjugates focused licensing
  • Distribution of Antibody Drug Conjugates focused licensing deals among market cap groups
  • Comparisons of different medicine groups in Antibody Drug Conjugates focused licensing
  • Companies currently engaging the most in Antibody Drug Conjugates focused licensing
  • Dynamics of varied licensing payments arrangements worldwide

Report useful to:

  • Antibody Drug Conjugates focused healthcare companies seeking licensing opportunities
  • Antibody Drug Conjugates focused healthcare companies seeking new market base
  • Executives of healthcare companies negotiating licensing for Antibody Drug Conjugates
  • Investors analyzing varied kinds of transaction options for Antibody Drug Conjugates focused licensing

Key Topics Covered

Introduction

Research Design

Chapter 1: Analysis of healthcare inventions with focus on Antibody Drug Conjugates licensed during the past five quarters

1.1 Number of licensing deals with focus on Antibody Drug Conjugates

1.2 Countries with most licensing deals with focus on Antibody Drug Conjugates

1.3 Healthcare sub-sectors with most licensing deals with focus on Antibody Drug Conjugates

1.4 Market capitalization groups with most licensing deals with focus on Antibody Drug Conjugates

1.5 Medicine groups with most licensing deals with focus on Antibody Drug Conjugates

1.6 Leading companies with most licensing deals with focus on Antibody Drug Conjugates

1.7 Licensing payment arrangements most followed in licensing deals with focus on Antibody Drug Conjugates

Chapter 2: Key licensing deals with focus on Antibody Drug Conjugates during the past five quarters - By type of licensing deal

Chapter 3: Global healthcare inventions with focus on Antibody Drug Conjugates licensed during the past five quarters - By region and company name

Chapter 4: Summary and conclusions

Appendices

Appendix 1 List of companies/institutes covered

a) By region, country and company name

b) By sub-industry, country and company name

c) By market capitalization group, country and company name

d) By medicine group, country and company name

e) By terms of payment, country and company name

Appendix 2 List of non-listed companies covered - By country and company name

Appendix 3 List of not-for-profit institutes covered - By country and institute name

Companies Mentioned

Alphabetical List of Sample 30 Companies/Institutes (of the total 60 companies covered) in the Report:

  • Advanced Proteome Therapeutics Corporation
  • Agensys, Inc
  • AstraZeneca plc
  • Avacta Group plc
  • Bach BioSciences
  • Bliss Biopharmaceutical (Hangzhou) Co., Ltd
  • Celgene Corporation
  • Cellectar Biosciences, Inc.
  • Clovis Oncology, Inc.
  • Corea Therapeutics, LLC
  • CytomX Therapeutics, Inc.
  • Daiichi Sankyo Co. Ltd.
  • Datta Meghe Institute of Medical Sciences
  • Distributed Bio, Inc.
  • GeNext Genomics Pvt. Ltd
  • Glycotope GmbH Biotech
  • Glythera Limited
  • GO Therapeutics Inc
  • H3 Biomedicine Inc.
  • Heidelberg Pharma AG
  • ImmunoBiochem Corporation
  • ImmunoGen, Inc.
  • Immunomedics, Inc.
  • Kanzen Co., Ltd
  • LegoChem Biosciences, Inc.
  • Magenta Therapeutics Inc
  • Merck & Co. Inc.
  • Merck KGaA
  • Mersana Therapeutics Inc.
  • Morphotek, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/si0iey

View source version on businesswire.com:https://www.businesswire.com/news/home/20190509005640/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Healthcare Services,Oncology Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/09/2019 10:45 AM/DISC: 05/09/2019 10:45 AM

http://www.businesswire.com/news/home/20190509005640/en